Skip to content
The Policy VaultThe Policy Vault

Stivarga (regorafenib)Medica

Gastrointestinal stromal tumor (GIST)

Initial criteria

  • age ≥ 18 years
  • EITHER (tried BOTH imatinib or Ayvakit (avapritinib) AND sunitinib or Sprycel (dasatinib)) OR used as first-line therapy for succinate dehydrogenase (SDH)-deficient disease

Approval duration

1 year